Quercetin is a flavonoid that is a natural compound that is abundant in fruits, vegetables and medical plants and has a wide range of pharmacological activities. This paper presents a detailed review of quercetin with regards to its chemistry, biological activities, pharmacological actions and future therapeutic expectations. In structure, quercetin has a polyphenolic structure having several hydroxyl groups which make it have high antioxidant properties.
With regard to its therapeutic value, quercetin has some limitations which include low bioavailability, low solubility, and high metabolism rate, which limit its clinical use. The latest developments in the drug delivery system such as nanoparticles and liposomal formulations have brought about a lot of improvements in its pharmacokinetic profile. Also, new clinical evidence points to its use in chronic illnesses like diabetes, cardiovascular conditions and neurodegenerative disorders. Analytical procedures of its identification and quantification, its safety and toxicological profile are also discussed in this manuscript. All in all, quercetin is a promising multifunctional bioflavonoid that has a great potential in future pharmaceutical and nutraceutical applications.

Background:
Burn injuries present a major clinical challenge due to their complexity and the limitations of conventional treatments in restoring functional and aesthetic skin. Stem cell-based therapies offer promising regenerative potential by enhancing wound healing, reducing inflammation, and promoting tissue regeneration. However, their clinical translation remains limited and fragmented across study types.
Objective:
To systematically evaluate the efficacy and safety of stem cell-based interventions—including mesenchymal stem cells (MSCs), epidermal stem cells (ESCs), induced pluripotent stem cells (iPSCs), and exosomes—for burn wound healing in preclinical and clinical studies.
Methods:
This review adhered to PRISMA 2020 guidelines. Four databases (PubMed, Embase, Scopus, Cochrane) were searched up to April 27, 2025. Eligible studies included randomized controlled trials and controlled preclinical studies evaluating burn wound healing outcomes with stem cell-based therapies. Risk of bias was assessed using RoB 2 and SYRCLE tools. A random-effects meta-analysis was conducted for compatible outcomes.
Results:
Four studies were included: one clinical trial, two preclinical RCTs, and one narrative review. Stem cell therapies improved wound closure, dermal thickness, angiogenesis, and inflammatory modulation. The meta-analysis of two preclinical studies showed a pooled standardized mean difference (SMD) of 1.15 (95% CI: 0.54 to 1.76), with moderate heterogeneity (I² = 49.4%). GRADE assessments rated the certainty of evidence as moderate for wound healing outcomes and low for safety.

Conclusion:
Stem cell-based interventions, particularly MSCs and exosome-derived products, demonstrate promising regenerative effects in burn wound models. While early-phase clinical findings suggest safety, evidence for efficacy in humans remains limited. Further high-quality trials are needed to support clinical adoption.

Breast cancer is the most frequently diagnosed cancer in women and remains a leading cause of cancer-related death worldwide. Its development is multifactorial, involving a complex interaction of genetic susceptibility, hormonal exposure, reproductive history, environmental influences, and modifiable lifestyle factors.
Hereditary mutations, particularly in BRCA1 and BRCA2, contribute substantially to risk in a smaller proportion of patients, while age, family history, obesity, alcohol intake, physical inactivity, and prolonged exposure to endogenous or exogenous estrogen influence a much larger population. The disease burden continues to increase globally, highlighting the need for early recognition of risk, effective screening strategies, and lifestyle-based prevention.
This review explores the major causes of breast cancer, explains biological mechanisms that underlie carcinogenesis, and discusses preventive and clinical implications. The paper is intended as a detailed academic review suitable for undergraduate, postgraduate, or nursing and medical coursework.

Most breakthroughs in medicine reach people only after passing through clinical trials. Starting with careful planning, these tests follow tough rules meant to protect everyone involved. Because they measure how well treatments work, researchers rely on them heavily when studying medicines or devices. From start to finish, each step checks safety, how the body handles a drug, and whether it actually helps patients. Only once results meet high standards do therapies move toward broader use across health systems.
This detailed look at clinical trials unpacks how they operate amid shifting markets and everyday medical practice, weaving together findings on trial stages, fresh approaches to study layouts, current rules that shape research, along with worldwide business patterns. Starting far back when testing treatments was basic, the piece follows the journey toward now - where advanced tech shapes complex, modern trial structures.
One decade ahead, the worldwide clinical trials sector could reach between USD 120 and 145 billion, up from about USD 64 to 67 billion in 2025, marking steady yearly gains near 5 to 8 percent. Behind this rise sits heavier spending on innovation within drug and bio-tech companies.
Chronic health conditions are spreading globally, pushing demand higher. New treatments targeting cancer, uncommon illnesses, plus biological medicines also add momentum. Each year brings more complex medical needs, which keeps trial activity climbing.
These days, how clinical trials are set up keeps changing fast. Instead of sticking to old formats, teams now test new structures - ones that adjust as they go, group multiple treatments, or focus on specific gene traits. Technology plays a big role here. Tools like smart algorithms, automated pattern detection, online data systems, body-worn monitors, and virtual care setups help bring patients in quicker.
Speed matters more than ever. Getting things done faster without losing quality has become a clear goal across research sites. Efficiency isn’t just talked about - it shows up in daily workflows. Digital support makes coordination smoother between doctors, participants, and analysts. Progress moves ahead even when people stay apart.
Putting patients first in study planning might help. When rules align across countries, things could shift. Full reporting of test results by law tends to support fairness. Without shared standards, gains may stay uneven. Growth in medical testing happens fast now - outcomes should reflect real needs everywhere.

Peptic ulcer disease (PUD), characterized by disruptions in the gastric or duodenal mucosa, remains a significant yet often overlooked gastrointestinal disorder globally. This review synthesizes current evidence on the epidemiology, pathophysiology, diagnosis, and management of stomach ulcers, emphasizing Helicobacter pylori infection and non-steroidal anti-inflammatory drug (NSAID) use as primary etiological factors Eradication regimens, and emerging approaches to mitigate complications such as bleeding and we highlight clinical guidelines, therapeutic strategies including proton pump inhibitors (PPIs) and perforation. The findings underscore the importance of early detection and preventive measures to reduce morbidity and healthcare burdens.

Cancer remains one of the leading causes of morbidity and mortality worldwide, characterized by uncontrolled cell proliferation, invasion, and metastasis. Despite advancements in chemotherapy, radiotherapy, and targeted therapy, these treatments are often associated with toxicity, resistance, and high cost. Herbal drugs, derived from medicinal plants, have emerged as promising alternatives or complementary approaches in cancer treatment due to their multi-targeted actions and relatively low toxicity. Phytochemicals such as flavonoids, alkaloids, terpenoids, and polyphenols exhibit anticancer activities through mechanisms including apoptosis induction, inhibition of angiogenesis, immune modulation, and suppression of tumor growth.
Recent research highlights that plant-derived compounds interact with multiple molecular pathways involved in carcinogenesis, offering advantages over single-target synthetic drugs. This review provides a comprehensive overview of herbal drugs used in cancer treatment, their phytochemical constituents, mechanisms of action, therapeutic applications, advantages, limitations, and future perspectives.

Intestinal biofilms play a critical role in shaping gut microbial ecology and have emerged as key drivers of dysbiosis, chronic inflammation, and impaired gut–brain communication. These structured microbial communities exhibit enhanced resistance to host defenses and antimicrobial agents, enabling persistent mucosal colonization and sustained neuroimmune activation. Growing evidence indicates that phytochemicals represent a promising class of antibiofilm agents capable of restoring microbial balance while supporting gut barrier integrity and neuroprotective signaling.
This review synthesizes current literature on biofilm-associated pathobionts and their impact on intestinal and neurological health, with a focus on the antibiofilm mechanisms of major phytochemical classes, including polyphenols, alkaloids, terpenoids, and quinones. Particular emphasis is placed on quorum-sensing inhibition, disruption of extracellular polymeric substances, modulation of microbial gene expression, and reshaping of gut microbiota composition. The role of phytochemicals in enhancing short-chain fatty acid production, strengthening epithelial tight junctions, and attenuating inflammatory pathways relevant to the gut–brain axis is critically examined.
Advances in nanotechnology-based delivery systems that improve phytochemical stability, bioavailability, and targeted intestinal release are also discussed, alongside insights from animal models used to evaluate gut–brain outcomes. Finally, translational challenges and future directions for integrating phytochemical antibiofilm strategies into functional foods and therapeutics are outlined. Collectively, this review highlights phytochemicals as multifunctional ecological modulators with significant potential for managing microbiota-driven intestinal and neurological disorders.